STEVENSON, Md., Aug. 14, 2013 (GLOBE NEWSWIRE) -- The securities litigation firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been filed in the Delaware Chancery Court on behalf of all stockholders of Optimer Pharmaceuticals, Inc. ("Optimer" or the "Company") (Nasdaq:OPTR) common stock.
According to the complaint, the proposed buyout provides for Optimer shareholders to receive $10.75 per share in cash for each share of Optimer common stock they own in addition to a Contingent Value Right ("CVR") which is expected to be publicly traded entitling the holder to receive an additional one-time cash payment of up to $5.00 for each share they own if certain net sales of DIFICID® (fidaxomicin) are achieved. The lawsuit alleges that the members of Optimer's Board of Directors have breached their fiduciary duties by agreeing to the proposed buyout for inadequate consideration and by agreeing to a series of deal protection provisions that, when viewed together, could potentially inhibit bidders from making a successful competing offer for the Company.
If you currently own common stock of Optimer and would like to learn more about the claims being asserted and your rights, you may email or call Brower Piven, who will, without obligation or cost to you, attempt to answer your questions. You may contact Brower Piven by email at firstname.lastname@example.org, by calling (410) 415-6616, or at Brower Piven, A Professional Corporation, 1925 Old Valley Road, Stevenson, Maryland 21153. Attorneys at Brower Piven have combined experience litigating securities and other class action cases of over 60 years.
CONTACT: Brower Piven, A Professional Corporation Stevenson, Maryland Charles J. Piven, (410) 415-6616 email@example.comSource: Brower Piven, A Professional Corporation